Zuo-wei Wang

发表

Discovery of IHMT-MST1-58 as a Novel, Potent, and Selective MST1 Inhibitor for the Treatment of Type 1/2 Diabetes.

Q. Liu, Ao-li Wang, F. Zou, 2022, Journal of medicinal chemistry.

Repurposing of the FGFR inhibitor AZD4547 as a potent inhibitor of necroptosis by selectively targeting RIPK1

Q. Liu, Juan Liu, Ao-li Wang, 2022, Acta Pharmacologica Sinica.

Osimertinib successfully combats EGFR-negative glioblastoma cells by inhibiting the MAPK pathway

Hong Wu, C. Niu, Zong-ru Jiang, 2020, Acta Pharmacologica Sinica.

Inhibition of the deubiquitinating enzyme USP47 as a novel targeted therapy for hematologic malignancies expressing mutant EZH2

W. Ni, J. Griffin, Q. Liu, 2022, Leukemia.

Discovery of IHMT-EZH2-115 as a Potent and Selective Enhancer of Zeste Homolog 2 (EZH2) Inhibitor for the Treatment of B-Cell Lymphomas.

Qingsong Liu, Xiaofei Liang, Q. Liu, 2021, Journal of medicinal chemistry.

Discovery of a novel and highly selective CDK9 kinase inhibitor (JSH-009) with potent antitumor efficacy in preclinical acute myeloid leukemia models

Q. Liu, Hong Wu, Zong-ru Jiang, 2019, Investigational New Drugs.

Osimertinib successfully combats EGFR-negative glioblastoma cells by inhibiting the MAPK pathway

Q. Liu, Hong Wu, Zong-ru Jiang, 2020, Acta Pharmacologica Sinica.

Discovery of a highly potent pan-RAF inhibitor IHMT-RAF-128 for cancer treatment.

Q. Liu, Zong-ru Jiang, Juan Liu, 2023, European journal of pharmacology.

Breakthrough infection elicits hypermutated IGHV3-53/3-66 public antibodies with broad and potent neutralizing activity against SARS-CoV-2 variants including BQ and XBB lineages

T. Zuo, Xixian Chen, Ling Li, 2023, bioRxiv.